Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor cell glycan–immune cell lectin receptor interface
- Molecular classification
- Other (interface of glycan structures and lectin receptors), Receptor (lectin receptor involved)
01
Overview
The tumor cell glycan–immune cell lectin receptor interface is a molecular interaction between altered glycan structures on the surface of tumor cells and glycan-binding lectin receptors (including C-type lectin receptors, galectins, and Siglecs) expressed on immune cells. This interface orchestrates critical immune checkpoint-like functions, promoting immune evasion and tumor progression by suppressing anti-tumor immune responses. Targeting the glycan–lectin interaction with biologics (such as antibodies or glycomimetic compounds) is considered an emerging immunotherapeutic approach in oncology, aiming to overcome resistance to conventional immune checkpoint inhibitors and re-invigorate anti-tumor immunity.
- Other names
- Tumor glycan–lectin checkpointGlyco-immune checkpointTumor glyco-immune interface
02
Mechanism of action
Blockade of glycan-lectin interaction to restore or enhance anti-tumor immunity; Inhibition of immunosuppressive signaling pathways induced by lectin receptor engagement
03
Biological functions
Immune response modulationImmune evasionImmune checkpoint regulationCell-cell interaction in the tumor microenvironment
04
Disease associations
CancerImmune evasionTumor progression
05
Safety considerations
Potential for broad immune modulation or autoimmunityOff-target effects due to lectin receptor roles in homeostasis and pathogen recognitionGlycan redundancy and heterogeneity may limit specificity of targeting strategies
06
Interacting drugs
No single drug; experimental therapeutics include inhibitors or antibodies targeting C-type lectin receptors (e.g., anti-DC-SIGN), Siglecs (e.g., anti-Siglec-7 or Siglec-9), galectins (e.g., galectin-3 inhibitors), and various glycomimetic molecules under preclinical/clinical development
07
Biomarkers
Aberrant glycosylation patterns (e.g., increased sialylation, fucosylated Lewis antigens, truncated O-glycans)Expression of specific lectin receptors on immune cells (e.g., DC-SIGN, Siglecs, galectins)Tumor glyco-code signature for immunotype stratification
Beyond the preview
Go deeper on Tumor cell glycan–immune cell lectin receptor interface.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tumor cell glycan–immune cell lectin receptor interface.